Vivimed Labs Limited (BOM:532660)

Market Cap	601.13M -43.8%
Revenue (ttm)	883.92M -35.5%
Net Income	-349.49M
EPS	-4.21
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	25,335
Average Volume	19,701
Open	7.56
Previous Close	7.64
Day's Range	7.26 - 7.71
52-Week Range	5.15 - 27.99
Beta	n/a
RSI	54.88
Earnings Date	May 29, 2026

About Vivimed Labs

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India. It operates through two segments, Speciality Chemicals Business and Pharma Business. The company provides APIs and intermediates to generic and ethical companies; and branded formulations in therapeutic segments, such as ophthalmic, nutraceuticals, dermatology, and pain, as well as contract manufacturing of capsules and tablets, syrups ...

• Industry: Chemicals and Allied Products
• Founded: 1988
• Employees: 586
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 532660

Financial Performance

In fiscal year 2025, Vivimed Labs's revenue was 1.21 billion, a decrease of -24.15% compared to the previous year's 1.59 billion. Losses were -319.61 million, -29.67% less than in 2024.